Indrová M - Search Results

1

Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes.

Vlková V, Štěpánek I, Hrušková V, Šenigl F, Mayerová V, Šrámek M, Šímová J, Bieblová J, Indrová M, Hejhal T, Dérian N, Klatzmann D, Six A, Reiniš M. Vlková V, et al. Among authors: indrova m. Oncotarget. 2014 Aug 30;5(16):6923-35. doi: 10.18632/oncotarget.2222. Oncotarget. 2014. PMID: 25071011 Free PMC article.

2

Immunization with MHC class I-negative but not -positive HPV16-associated tumour cells inhibits growth of MHC class I-negative tumours.

Reinis M, Símová J, Indrová M, Bieblová J, Pribylová H, Moravcová S, Jandlová T, Bubeník J. Reinis M, et al. Among authors: indrova m. Int J Oncol. 2007 Apr;30(4):1011-7. Int J Oncol. 2007. PMID: 17332942

3

CpG oligodeoxynucleotides are effective in therapy of minimal residual tumour disease after chemotherapy or surgery in a murine model of MHC class I-deficient, HPV16-associated tumours.

Reinis M, Símová J, Indrová M, Bieblová J, Bubeník J. Reinis M, et al. Among authors: indrova m. Int J Oncol. 2007 May;30(5):1247-51. Int J Oncol. 2007. PMID: 17390028

4

Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours.

Manning J, Indrova M, Lubyova B, Pribylova H, Bieblova J, Hejnar J, Simova J, Jandlova T, Bubenik J, Reinis M. Manning J, et al. Among authors: indrova m. Immunology. 2008 Feb;123(2):218-27. doi: 10.1111/j.1365-2567.2007.02689.x. Epub 2007 Aug 28. Immunology. 2008. PMID: 17725605 Free PMC article.

5

Tumour-inhibitory and antimetastatic effects of IL-2 in mice carrying MHC class I- tumours of HPV16 origin.

Indrová M, Bubeník J, Mikysková R, Vonka V, Smahel M, Zák R, Símová J, Bieblová J, Mendoza L, Jandlová T. Indrová M, et al. Int J Oncol. 2002 Mar;20(3):643-6. Int J Oncol. 2002. PMID: 11836582

6

Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.

Mikysková R, Bubeník J, Vonka V, Smahel M, Indrova M, Bieblová J, Símová J, Jandlová T. Mikysková R, et al. Among authors: indrova m. Int J Oncol. 2005 Feb;26(2):521-7. Int J Oncol. 2005. PMID: 15645139

7

Chemotherapy, IL-12 gene therapy and combined adjuvant therapy of HPV 16-associated MHC class I-proficient and -deficient tumours.

Indrová M, Bieblová J, Jandlová T, Vonka V, Pajtasz-Piasecka E, Reinis M. Indrová M, et al. Int J Oncol. 2006 Jan;28(1):253-9. Int J Oncol. 2006. PMID: 16328003

8

IL-12 immunotherapy of minimal residual disease in murine models of HPV16-associated tumours: induction of immune responses, cytokine production and kinetics of immune cell subsets.

Indrová M, Bieblová J, Bubeník J, Reinis M. Indrová M, et al. Int J Oncol. 2008 Feb;32(2):499-507. Int J Oncol. 2008. PMID: 18202774

9

Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy.

Símová J, Indrová M, Bieblová J, Mikysková R, Bubeník J, Reinis M. Símová J, et al. Among authors: indrova m. Int J Cancer. 2010 Jun 15;126(12):2997-3004. doi: 10.1002/ijc.24887. Int J Cancer. 2010. PMID: 19739073 Free article.

10

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines.

Reinis M, Stepanek I, Simova J, Bieblova J, Pribylova H, Indrova M, Bubenik J. Reinis M, et al. Among authors: indrova m. Int J Oncol. 2010 Mar;36(3):545-51. doi: 10.3892/ijo_00000528. Int J Oncol. 2010. PMID: 20126973

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

94 results

Search Page